GregJonesLaw_10Q02_2013-03-13_Wed_Vimpat Approved as Treatment for Partial Adjunctive Onset Epilepsy

Vimpat Approved as Treatment for Partial Adjunctive Onset Epilepsy

The European Union has approved Vimpat (lacosamide) for initiation as a single dose and twice daily dose regimen for the treatment of partial adjunctive onset epilepsy.

“As a leader in epilepsy, UCB is committed to delivering solutions aimed at improving the lives of people with epilepsy and advancing current standards of care,” says Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President of the biopharma company UCB. “The single loading dose option is available for all formulations of lacosamide in the European Union and should help to fill an important treatment gap in adjunctive options for patients with partial onset seizures. It allows for the rapid attainment of lacosamide steady state plasma concentration in situations where it is deemed appropriate by the prescribing physician.”

“A single loading dose option allows for the rapid initiation of adjunctive lacosamide treatment for partial onset seizures in adults with epilepsy when required,” said Dr. Nathan Fountain, Professor of Neurology and Director of the Comprehensive Epilepsy Program at the University of Virginia in Charlottesville, Va. “The open-label intravenous study showed that rapid initiation of adjunctive lacosamide treatment was generally well-tolerated by patients requiring a loading dose.”

Vimpat is currently believed to be a safer alternative to other popular epilepsy drugs, one of which may be Topamax, which is used to prevent seizures. With epilepsy being such a common condition (affecting millions of children and adults worldwide), it is surprising that finding the right medication to treat the condition has been so difficult. One of the reasons for that may be because doctors often don’t diagnose the condition early enough, which ends up making them prescribe various different medications in an effort to treat symptoms. Even after the condition is diagnosed, many doctors end up guessing at which dosages to give patients before finding the right treatment for each individual case. This trial and error method of treatment can be dangerous since some of these drugs, like Topamax, can be very dangerous.

For example, side effects linked to Topamax use include birth defects in babies whose mothers take the pills while pregnant. Some of those birth defects include PPHN, oral clefts, spina bifida and neural tube defects.

If your baby has suffered from birth defects after being exposed to Topamax in-utero, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Topamax lawsuits and may be able to help you recover money for your child’s injury.